The decision broadens Jaypirca’s label and converts the December 2023 accelerated approval to a traditional approval status.

In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met ...

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety ...

With both a label expansion and a conversion to a full approval, Eli Lilly has earned the FDA’s go-ahead to act on the ...

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Federal regulators put off a decision on whether to approve an Eli Lilly Alzheimer’s drug by making an unusual request to have outside advisers look at the treatment. Lilly had expected the Food and ...

Eli Lilly said Monday that it's reducing the price of its popular weight-loss drug Zepbound on its LillyDirect platform, ...

The world’s largest drugmaker, Eli Lilly & Co., just notched another milestone: it’s the first health-care company to cross the $1 trillion threshold as investors bet big on the drugmaker’s ...

Mounjaro and Pfizer’s ($PFE) cancer drugs were added to China’s state-run health insurance scheme, according to the country’s ...

With the best-selling medication in the world, tirzepatide, and a record-setting $1 trillion valuation to go with it, Eli ...